Clinical observation of guselkumab in the treatment of 23 cases of moderate to severe plaque psoriasis

Abstract

Objective To observe the clinical efficacy and safety of guselkumab injection in the treatment of moderate to severe plaque psoriasis. Methods Twenty three patients with moderate to severe plaque psoriasis were treated with subcutaneous injection of guselkumab at a dose of 100 mg at weeks 0 and 4, followed by once every 8 weeks. The psoriasis lesion area and severity index (PASI) were evaluated at weeks 4 and 12, and adverse reactions were recorded. Results All 23 patients received treatment at least 3 times (0, 4, 12 weeks). At week 12, 23 patients (100%) achieved PASI 75 or above, including PASI 90 in 19 patients (82.61%) and PASI 100 in 10 patients (43.48%). No serious adverse reactions were observed. Conclusions Guselkumab is safe and effective for moderate to severe plaque psoriasis, and can rapidly improve skin lesions. It provides a new treatment option for patients with moderate to severe plaque psoriasis.

Keywords

• psoriasis
• biological agents
• interleukin-23
• guselkumab